Literature DB >> 30123739

Hypofractionated whole breast irradiation is cost-effective-but is that enough to change practice?

Apar Gupta1, Nisha Ohri1, Bruce G Haffty1.   

Abstract

Entities:  

Year:  2018        PMID： 30123739      PMCID： PMC6097715          DOI： 10.21037/tcr.2018.03.20

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  24 in total

1.  A population-based study of the fractionation of postlumpectomy breast radiation therapy.

Authors:  Allison Ashworth; Weidong Kong; Timothy Whelan; William J Mackillop
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-20       Impact factor: 7.038

2.  A cost comparison analysis of adjuvant radiation therapy techniques after breast-conserving surgery.

Authors:  Thomas Lanni; Martin Keisch; Chirag Shah; Jessica Wobb; Larry Kestin; Frank Vicini
Journal:  Breast J       Date:  2013-01-07       Impact factor: 2.431

3.  Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation.

Authors:  Cameron W Swanick; Xiudong Lei; Simona F Shaitelman; Pamela J Schlembach; Elizabeth S Bloom; Michelle C Fingeret; Eric A Strom; Welela Tereffe; Wendy A Woodward; Michael C Stauder; Tomas Dvorak; Alastair M Thompson; Thomas A Buchholz; Benjamin D Smith
Journal:  Cancer       Date:  2016-06-15       Impact factor: 6.860

4.  Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials.

Authors:  Reshma Jagsi; Aaron D Falchook; Laura H Hendrix; Heather Curry; Ronald C Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-01       Impact factor: 7.038

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial.

Authors:  Atif J Khan; Matthew M Poppe; Sharad Goyal; Kristine E Kokeny; Thomas Kearney; Laurie Kirstein; Deborah Toppmeyer; Dirk F Moore; Chunxia Chen; David K Gaffney; Bruce G Haffty
Journal:  J Clin Oncol       Date:  2017-05-01       Impact factor: 44.544

Review 7.  Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline.

Authors:  Benjamin D Smith; Soren M Bentzen; Candace R Correa; Carol A Hahn; Patricia H Hardenbergh; Geoffrey S Ibbott; Beryl McCormick; Julie R McQueen; Lori J Pierce; Simon N Powell; Abram Recht; Alphonse G Taghian; Frank A Vicini; Julia R White; Bruce G Haffty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-16       Impact factor: 7.038

8.  Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.

Authors:  Benjamin D Smith; Jennifer R Bellon; Rachel Blitzblau; Gary Freedman; Bruce Haffty; Carol Hahn; Francine Halberg; Karen Hoffman; Kathleen Horst; Jean Moran; Caroline Patton; Jane Perlmutter; Laura Warren; Timothy Whelan; Jean L Wright; Reshma Jagsi
Journal:  Pract Radiat Oncol       Date:  2018-03-12

9.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Authors:  Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold
Journal:  Lancet Oncol       Date:  2013-09-19       Impact factor: 41.316

10.  Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.

Authors:  Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321
View more
  5 in total

1.  Hypofractionated Radiation Therapy for Breast Cancer: Financial Risk and Expenditures in the United States, 2008 to 2017.

Authors:  Loren Saulsberry; Chuanhong Liao; Dezheng Huo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-10-09       Impact factor: 8.013

2.  Can the Adoption of Hypofractionation Guidelines Expand Global Radiotherapy Access? An Analysis for Breast and Prostate Radiotherapy.

Authors:  Omoruyi Credit Irabor; William Swanson; Fiza Shaukat; Johanna Wirtz; Abba Aji Mallum; Twalib Ngoma; Ahmed Elzawawy; Paul Nguyen; Luca Incrocci; Wilfred Ngwa
Journal:  JCO Glob Oncol       Date:  2020-04

3.  Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.

Authors:  Hilde Van Parijs; Vincent Vinh-Hung; Christel Fontaine; Guy Storme; Claire Verschraegen; Dung M Nguyen; Nele Adriaenssens; Nam P Nguyen; Olena Gorobets; Mark De Ridder
Journal:  BMC Cancer       Date:  2021-11-04       Impact factor: 4.430

4.  Has Hypofractionated Whole-Breast Radiation Therapy Become the Standard of Care in the United States? An Updated Report from National Cancer Database.

Authors:  Minji M Kang; Yasmin Hasan; Joseph Waller; Loren Saulsberry; Dezheng Huo
Journal:  Clin Breast Cancer       Date:  2021-06-07       Impact factor: 3.225

5.  Physician trajectories of abandoning long-course breast radiotherapy and their cost impact.

Authors:  Xiao Xu; Pamela R Soulos; Jeph Herrin; Shi-Yi Wang; Craig Evan Pollack; Suzanne B Evans; James B Yu; Cary P Gross
Journal:  Health Serv Res       Date:  2020-10-18       Impact factor: 3.734
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.